乳糖菌 (Lacticaseibacillus rhamnosus) MS27 通过调节肠道微生物群,有可能预防性结肠炎
Jie Zhang1,2, Jiakun Shen2, Linbao Ji2
1School of Public Health, North China University of Science and Technology, Tangshan 063210, China.
International journal of molecular sciences
|December 11, 2025
概括
一种新的益生菌Lacticaseibacillus rhamnosus MS27有效地缓解了小鼠的性结肠炎 (UC) 症状. 这种有益的细菌调节肠道微生物群和宿主免疫反应,为炎症性肠病提供了潜在的治疗策略.
科学领域:
- 微生物学和免疫学
- 胃肠病学 胃肠病学
- 益生菌研究 益生菌研究
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 益生菌正在研究它们对调节肠道微生物群和在炎症条件下免疫反应的潜力.
- 新型菌株Lacticaseibacillus rhamnosus MS27因其潜在的治疗性质而被分离出来.
研究的目的:
- 评估Lacticaseibacillus rhamnosus MS27作为缓解性结肠炎 (UC) 的潜在益生菌.
- 研究L. rhamnosus MS27对肠道微生物生态和宿主分子机制的影响.
- 评估该菌株的生物化学特征和安全概况.
主要方法:
- 生物化学鉴定,抗生素敏感性和L. rhamnosus MS27的抗菌活性评估.
- 在甲 (DSS) 诱导的大肠炎小鼠模型中对L. rhamnosus MS27的评估.
- 16S rRNA微生物组和真核转录组分析以确定对肠道微生物群和宿主基因表达的影响.
主要成果:
- L. rhamnosus MS27表现出耐酸性,并利用各种碳水化合物,对特定抗生素表现出敏感性.
- 益生菌显著增加了有益的微生物,如Akkermansia和Limosilactobacillus reuteri,同时减少了潜在的病原体.
- 转录组分析显示Igkv16-104和C1qtnf3的下调,免疫相关基因的显著改变,包括MHC.
结论:
- 在小鼠模型中,L. rhamnosus MS27有效地减轻与性结肠炎相关的炎症表型.
- 该菌株表现出独特的代谢特征,并调节肠道微生物群,包括Turicibacter,以影响宿主免疫功能.
- L. rhamnosus MS27代表了一个有希望的新型益生菌候选人,用于管理炎症性肠道疾病.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
424
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424
Drugs for Treatment of Constipation-Predominant IBS
676
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
676
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
614
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
614
Drugs for Treatment of Diarrhea-Predominant IBS
598
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
598
Inflammatory Bowel Disease IV: Pharmacological Management
445
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
445
Irritable Bowel Syndrome I: Introduction
890
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
890


